{"nctId":"NCT03353350","briefTitle":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise","startDateStruct":{"date":"2017-12-05","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":406,"armGroups":[{"label":"Efpeglenatide 2mg","type":"EXPERIMENTAL","interventionNames":["Drug: efpeglenatide (SAR439977)"]},{"label":"Efpeglenatide 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: efpeglenatide (SAR439977)"]},{"label":"Efpeglenatide 6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: efpeglenatide (SAR439977)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"efpeglenatide (SAR439977)","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participants must be at least 18 years of age at the time of signing the informed consent.\n* Participants with T2DM, and treated with diet and exercise.\n* Hemoglobin A1c between 7.0% and 10.0% (inclusive) measured by the central laboratory at Screening.\n\nExclusion criteria:\n\n* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease within 6 months prior to Screening or history of surgery affecting gastric emptying.\n* History of pancreatitis (unless pancreatitis was related to gallstone and cholecystectomy has been performed) and pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, and pancreatectomy.\n* Personal or family history of Medullary Thyroidian Cancer (MTC) or genetic conditions that predisposes to MTC (eg multiple endocrine neoplasia syndromes).\n* Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months of screening) or planned: intravitreal injections or laser or vitrectomy surgery.\n* Body weight change of ≥5 kg within the last 3 months prior to Screening.\n* Systolic blood pressure \\>180 mmHg and/or diastolic blood pressure \\>100 mmHg at Randomization.\n* End-stage renal disease as defined by estimated glomerular filtration rate (eGFR , by Modification of Diet in Renal Disease \\[MDRD\\]) of \\<15 mL/min/1.73 m2.\n* Laboratory findings at the Screening Visit:\n* Alanine aminotransferase (ALT ) or aspartate aminotransferase (AST ) \\>3 times the upper limit of the normal (ULN ) or total bilirubin \\>1.5 times the ULN (except in case of documented Gilbert's syndrome).\n* Amylase and/or lipase: \\>3 times the ULN laboratory range.\n* Calcitonin ≥5.9 pmol/L (20 pg/mL).\n* Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to Screening, or planned during study period.\n* History of drug or alcohol abuse within 6 months prior to the time of Screening.\n* Pregnant (demonstrated by serum pregnancy test at Screening) or breast-feeding women.\n* Women of childbearing potential not willing to use highly effective method(s) of birth control during the study period and for at least 5 weeks after the last dose of study intervention.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycated Hemoglobin (HbA1c) (%)","description":"Change from Baseline to Week 30 in HbA1c","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"1.16"},{"groupId":"OG001","value":"-1.14","spread":"0.96"},{"groupId":"OG002","value":"-1.48","spread":"1.01"},{"groupId":"OG003","value":"-1.59","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (%)","description":"Change from Baseline to Week 56 in HbA1c","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"1.18"},{"groupId":"OG001","value":"-1.18","spread":"0.79"},{"groupId":"OG002","value":"-1.51","spread":"0.99"},{"groupId":"OG003","value":"-1.51","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change from Baseline to Week 30 in FPG","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.59","spread":"2.13"},{"groupId":"OG001","value":"-0.87","spread":"3.27"},{"groupId":"OG002","value":"6.84","spread":"1.57"},{"groupId":"OG003","value":"6.55","spread":"1.30"}]}]}]},{"type":"SECONDARY","title":"HbA1c <7%","description":"Number of participants with HbA1c \\<7.0% at Week 30","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight at Week 30","description":"Change from Baseline to Week 30 in body weight","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.35","spread":"3.15"},{"groupId":"OG001","value":"-1.01","spread":"3.66"},{"groupId":"OG002","value":"-3.34","spread":"4.19"},{"groupId":"OG003","value":"-3.19","spread":"4.77"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight at Week 56","description":"Change from Baseline to Week 56 in body weight","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","spread":"4.19"},{"groupId":"OG001","value":"-0.94","spread":"4.96"},{"groupId":"OG002","value":"-3.24","spread":"6.42"},{"groupId":"OG003","value":"-1.82","spread":"5.52"}]}]}]},{"type":"SECONDARY","title":"Hypoglycemic Participants","description":"Number of participants with at least 1 hypoglycemic event during treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Hypoglycemic Events","description":"Number of hypoglycemic events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Emergent Adverse Events (TEAEs)","description":"Number of participants with TEAEs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":102},"commonTop":["Diarrhoea","Nausea","Constipation","Headache","Injection site pain"]}}}